Figure 1
From: Cost-effectiveness of enzyme replacement therapy for Fabry disease
Cost-effectiveness acceptability curves of ERT versus no treatment for various levels of willingness-to-pay per QALY after 1,000 runs in a Monte Carlo simulation of beta-distributed state transition probabilities. The proportions of net monetary benefits larger than zero for these willingness-to-pay levels represent the probabilities of ERT being cost-effective in comparison with standard medical care and are reported in the cost-effectiveness acceptability curve.